Donor choice according to age for allo-SCT for AML in complete remission

作者：Ayuk F^*; Zabelina T; Wortmann F; Alchalby H; Wolschke C; Lellek H; Bacher U; Zander A; Kroeger N

来源：Bone Marrow Transplantation, 2013, 48(8): 1028-1032.

DOI：10.1038/bmt.2013.14

• donor
• age
• AML

In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD <= 39 years vs MRD > 39 years (66% vs 34%, P = 0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD <= 39 years, both MRD > 39 years (relative risk (RR): 4.31, P = 0.001) and UD > 39 years (RR: 2.14, P = 0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P = 0.02). Subgroup analyses of patients >= 50 years (n = 76) revealed similar results, with 5-yr OS of 62% for UD <= 39 yrs and 26% for MRD > 39 yrs (P = 0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

• 出版日期2013-8